Workflow
These Analysts Lower Their Forecasts On AdaptHealth Following Weak Sales
AHCOAdaptHealth(AHCO) Benzinga·2024-11-06 19:13

Core Insights - AdaptHealth Corp. reported third-quarter sales of 805.86million,missingtheanalystconsensusestimateof805.86 million, missing the analyst consensus estimate of 809.30 million [1] - The company revised its FY24 net revenue guidance from a range of 3.255billion−3.255 billion - 3.315 billion to 3.220billion−3.220 billion - 3.260 billion [2] - Following the earnings announcement, AdaptHealth shares gained 8.4%, trading at 9.95[2]AnalystRatingsandPriceTargets−BairdanalystEricColdwellmaintainedanOutperformratingbutloweredthepricetargetfrom9.95 [2] Analyst Ratings and Price Targets - Baird analyst Eric Coldwell maintained an Outperform rating but lowered the price target from 16 to 14[3]−CanaccordGenuityanalystRichardClosemaintainedaBuyratingandcutthepricetargetfrom14 [3] - Canaccord Genuity analyst Richard Close maintained a Buy rating and cut the price target from 14 to 13[3]−UBSanalystWhitMayomaintainedaBuyratingandloweredthepricetargetfrom13 [3] - UBS analyst Whit Mayo maintained a Buy rating and lowered the price target from 13 to 12[3]−TheconsensuspricetargetforAdaptHealthis12 [3] - The consensus price target for AdaptHealth is 13.48 based on ratings from 10 analysts, with a high of 30andalowof30 and a low of 6.5 [4] - The average price target from the most recent ratings implies a 31.58% upside for AdaptHealth Corp [4]